A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2
Related Posts
Jia Q, Bielefeldt-Ohmann H, Masleša-Galić S, Bowen RA, Horwitz MA. Universal Bacterium-Vectored COVID-19 Vaccine Expressing Early SARS-CoV-2 Conserved Proteins Cross-Protects Against Late Variants in Hamsters.[...]
Sandigo-Saballos I, Montero S, Lee P, Lee H, Chen KT. Less is More: A Cost and Environmental Waste Analysis in Nonadherence to Antibiotic Prophylaxis Guidelines[...]
Ertem Z, Danesharasteh A, Anand ST, Jackson NJ, Nelson RE, Schechter-Perkins EM, Fisher L, Doron S, Branch-Elliman W. Impact of lifting school mask mandates on[...]